Kim Paul forfeited 2,087 Fulgent Genetics shares at $19.59 per share on 2026-09-01, leaving an ownership position of 356,543 shares. For investors, the transaction identifies both the per-share value attached to the forfeited stock and the CFO and Treasurer’s reported holding afterward.
Key Highlights
- Kim Paul serves as Fulgent Genetics’ CFO and Treasurer.
- The transaction was recorded under SEC code F.
- The reported transaction price was $19.59 per share.
Fulgent Genetics (NASDAQ: FLGT) reported that Kim Paul forfeited 2,087 shares on 1 September 2026, with 356,543 shares remaining in the reported holding afterward. The transaction was priced at $19.59 per share.
Kim Paul’s Fulgent Genetics Share Forfeiture
Kim Paul is identified as Fulgent Genetics’ CFO and Treasurer. The transaction carries SEC transaction code F, and the reported post-transaction ownership figure is 356,543 shares. The per-share amount attached to the forfeiture was $19.59. The transaction records a change in Kim Paul’s reported Fulgent Genetics holdings. The source identifies the forfeited amount, the price assigned to each share and the resulting ownership position in the same transaction record.
FAQs
Q: What happened in Kim Paul’s Fulgent Genetics insider transaction?
A: According to the Form 4, Kim Paul forfeited 2,087 Fulgent Genetics shares on 1 September 2026. The filing reported that Kim Paul owned 356,543 shares after the transaction.
Q: At what price did Kim Paul forfeit Fulgent Genetics shares?
A: The Form 4 reported a forfeiture price of $19.59 per share on 1 September 2026. It identifies Kim Paul as Fulgent Genetics’ CFO and Treasurer.
Q: How many Fulgent Genetics shares did Kim Paul own after the transaction?
A: Following the transaction, the filing reported that Kim Paul owned 356,543 Fulgent Genetics shares. The transaction itself involved the forfeiture of 2,087 shares.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.